Altered bile acids profile is a risk factor for hyperandrogenism in lean women with PCOS: a case control study.
Bile acids
Hyperandrogenism
Metabolomics
Polycystic ovary syndrome
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
31 Oct 2024
31 Oct 2024
Historique:
received:
05
05
2024
accepted:
24
10
2024
medline:
1
11
2024
pubmed:
1
11
2024
entrez:
1
11
2024
Statut:
epublish
Résumé
The levels of fasting-state serum bile acids (BAs) in individuals with polycystic ovary syndrome (PCOS) differ from those of control subjects. However, there is a lack of research on the BAs profile in lean women with PCOS and whether these changes are linked to the host metabolism. Therefore, our objective was to investigate the synthesis and metabolism of serum BAs in lean women with PCOS and assess the correlation between BAs and clinical characteristics. This study employed a cross-sectional design of lean women with PCOS (n = 240) in comparison to a control group (n = 80) consisting of healthy lean women. The findings revealed significant increases in the levels of non-12-OH BAs and chenodeoxycholic acid (CDCA)% (both P < 0.05) in lean women with PCOS. Additionally, a positive correlation was observed between CDCA% and total testosterone (T) (r = 0.130, P = 0.044) and free androgen index (FAI) (r = 0.153, P = 0.019). Furthermore, a decreased ratio of cholic acid/chenodeoxycholic acid (CA/CDCA) (P < 0.001) was observed in lean women with PCOS, suggesting the depletion or downregulation of CYP8B1. Receiver operating characteristic curve analysis indicated that the combination of CDCA/CA and DHEAS could potentially be used as a characteristic factor for PCOS in lean women. It is possible that enzymatic modifications in the liver could play a role in regulating hyperandrogenism in this specific subgroup of lean women with PCOS.
Identifiants
pubmed: 39482365
doi: 10.1038/s41598-024-77645-7
pii: 10.1038/s41598-024-77645-7
doi:
Substances chimiques
Bile Acids and Salts
0
Chenodeoxycholic Acid
0GEI24LG0J
Testosterone
3XMK78S47O
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
26215Subventions
Organisme : National Natural Science Foundation of China
ID : 82170807
Organisme : Medical Guidance Science and Technology Support Projects of Shanghai Municipal Science and Technology Commission
ID : 18411968700
Organisme : Natural Science Foundation of Shanghai
ID : 12ZR1417800
Informations de copyright
© 2024. The Author(s).
Références
AZZIZ, R. et al. Polycystic ovary syndrome. Nat. Rev. Dis. Primers 2, 16057 (2016).
doi: 10.1038/nrdp.2016.57
pubmed: 27510637
GOODARZI M O, DUMESIC D A, CHAZENBALK, G. et al. Polycystic ovary syndrome: etiology, pathogenesis and diagnosis.Nat. Rev. Endocrinol. 7 (4), 219–231 (2011).
doi: 10.1038/nrendo.2010.217
pubmed: 21263450
AMSTERDAM E A-S R P C W & G. Consensus on women’s health aspects of polycystic ovary syndrome (PCOS).Hum. Reprod. 27 (1), 14–24 (2012).
doi: 10.1093/humrep/der396
IDICULA-THOMAS, S. & GAWDE, U. Meta-analysis of gene expression profiles of lean and obese PCOS to identify differentially regulated pathways and risk of comorbidities. Comput. Struct. Biotechnol. J. 18, 1735–1745 (2020).
doi: 10.1016/j.csbj.2020.06.023
pubmed: 32695266
TOOSY, S., SODI, R. & PAPPACHAN, J. M. Lean polycystic ovary syndrome (PCOS): an evidence-based practical approach. J. Diabetes Metab. Disord 17 (2), 277–285 (2018).
doi: 10.1007/s40200-018-0371-5
pubmed: 30918863
CHANG A Y et al. Combining a nontargeted and targeted metabolomics approach to identify metabolic pathways significantly altered in polycystic ovary syndrome. Metabolism 71, 52–63 (2017).
doi: 10.1016/j.metabol.2017.03.002
pubmed: 28521878
HU, S. U. N. L. & LIU, W. Metabonomics reveals plasma metabolic changes and inflammatory marker in polycystic ovary syndrome patients. J. Proteome Res. 11 (5), 2937–2946 (2012).
doi: 10.1021/pr3000317
pubmed: 22428626
QI, X. & YUN, C. Gut microbiota-bile acid-interleukin-22 axis orchestrates polycystic ovary syndrome. Nat. Med. 25 (8), 1225–1233 (2019).
doi: 10.1038/s41591-019-0509-0
pubmed: 31332392
STAELS, B. & FONSECA, V. A. Bile acids and metabolic regulation: mechanisms and clinical responses to bile acid sequestration. Diabetes Care 32 (Suppl 2(Suppl 2), S237–S245 (2009).
doi: 10.2337/dc09-S355
pubmed: 19875558
WEI, M. et al. A dysregulated bile acid-gut microbiota axis contributes to obesity susceptibility.EBioMedicine 55, 102766 (2020).
doi: 10.1016/j.ebiom.2020.102766
pubmed: 32408110
WAHLSTRÖM, A. et al. Intestinal crosstalk between bile acids and microbiota and its impact on host metabolism.Cell. Metab. 24 (1), 41–50 (2016).
doi: 10.1016/j.cmet.2016.05.005
pubmed: 27320064
DAWSON P A, KARPEN, S. J. Intestinal transport and metabolism of bile acids. J. Lipid Res. 56 (6), 1085–1099 (2015).
doi: 10.1194/jlr.R054114
pubmed: 25210150
RIDLON, J. M. & KANG D J HYLEMON P B. bile salt biotransformations by human intestinal bacteria. J. Lipid Res. 47 (2), 241–259 (2006).
doi: 10.1194/jlr.R500013-JLR200
pubmed: 16299351
MOLINARO, A., WAHLSTRÖM, A. & MARSCHALL, H. U. Role of bile acids in metabolic control. Trends Endocrinol. Metab. 29 (1), 31–41 (2018).
doi: 10.1016/j.tem.2017.11.002
pubmed: 29195686
PURI, P. et al. The presence and severity of nonalcoholic steatohepatitis is associated with specific changes in circulating bile acids. Hepatology 67 (2), 534–548 (2018).
doi: 10.1002/hep.29359
pubmed: 28696585
CHÁVEZ-TALAVERA O, HAAS, J. et al. Bile acid alterations in nonalcoholic fatty liver disease, obesity, insulin resistance and type 2 diabetes: what do the human studies tell? Curr. Opin. Lipidol. 30 (3), 244–254 (2019).
doi: 10.1097/MOL.0000000000000597
pubmed: 30893108
ZHANG, B. et al. Increased circulating conjugated primary bile acids are associated with hyperandrogenism in women with polycystic ovary syndrome. J. Steroid Biochem. Mol. Biol. 189, 171–175 (2019).
doi: 10.1016/j.jsbmb.2019.03.005
pubmed: 30849463
JIA, C. et al. Serum metabolomics analysis of patients with polycystic ovary syndrome by mass spectrometry. Mol. Reprod. Dev. 86 (3), 292–297 (2019).
doi: 10.1002/mrd.23104
pubmed: 30624822
Physical status. The use and Interpretation of Anthropometry. Report of a WHO Expert Committee 8541–452 (World Health Organ Tech Rep Ser, 1995).
ROTTERDAM E A-S P C W G Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil. Steril. 81 (1), 19–25 (2004).
doi: 10.1016/j.fertnstert.2003.10.004
TEEDE H J et al. Recommendations from the 2023 International evidence-based guideline for the assessment and management of polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 108 (10), 2447–2469 (2023).
doi: 10.1210/clinem/dgad463
pubmed: 37580314
CHRIST J P & CEDARS M I Current guidelines for diagnosing PCOS. Diagnostics (Basel), 13(6). (2023).
MATTHEWS D R et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28 (7), 412–419 (1985).
doi: 10.1007/BF00280883
pubmed: 3899825
SELTZER, H. S. et al. Insulin secretion in response to glycemic stimulus: relation of delayed initial release to carbohydrate intolerance in mild diabetes mellitus. J. Clin. Invest. 46 (3), 323–335 (1967).
doi: 10.1172/JCI105534
pubmed: 6023769
KAHN S E et al. Quantification of the relationship between insulin sensitivity and beta-cell function in human subjects. Evidence for a hyperbolic function. Diabetes 42 (11), 1663–1672 (1993).
doi: 10.2337/diab.42.11.1663
pubmed: 8405710
MATSUDA, M. & DEFRONZO R A. insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 22 (9), 1462–1470 (1999).
doi: 10.2337/diacare.22.9.1462
pubmed: 10480510
ALBAREDA, M. et al. Assessment of insulin sensitivity and beta-cell function from measurements in the fasting state and during an oral glucose tolerance test. Diabetologia 43 (12), 1507–1511 (2000).
doi: 10.1007/s001250051561
pubmed: 11151759
WANG, C. et al. Measurement of total serum testosterone in adult men: comparison of current laboratory methods versus liquid chromatography-tandem mass spectrometry. J. Clin. Endocrinol. Metab. 89 (2), 534–543 (2004).
doi: 10.1210/jc.2003-031287
pubmed: 14764758
JONES H, SPRUNG V S, PUGH C, J. et al. Polycystic ovary syndrome with hyperandrogenism is characterized by an increased risk of hepatic steatosis compared to nonhyperandrogenic PCOS phenotypes and healthy controls, independent of obesity and insulin resistance. J. Clin. Endocrinol. Metab. 97 (10), 3709–3716 (2012).
doi: 10.1210/jc.2012-1382
pubmed: 22837189
CHOUCAIR, I. et al. Quantification of bile acids: a mass spectrometry platform for studying gut microbe connection to metabolic diseases. J. Lipid Res. 61 (2), 159–177 (2020).
doi: 10.1194/jlr.RA119000311
pubmed: 31818878
CHÁVEZ-TALAVERA O, TAILLEUX, A. et al. Bile acid control of metabolism and inflammation in obesity, type 2 diabetes, dyslipidemia, and nonalcoholic fatty liver disease. Gastroenterology 152 (7), 1679–1694 (2017). e3.
doi: 10.1053/j.gastro.2017.01.055
pubmed: 28214524
BJÖRKHEM, I. & ARAYA, Z. Differences in the regulation of the classical and the alternative pathway for bile acid synthesis in human liver. No coordinate regulation of CYP7A1 and CYP27A1. J. Biol. Chem. 277 (30), 26804–26807 (2002).
doi: 10.1074/jbc.M202343200
pubmed: 12011083
MONTE M J, MARIN J J, ANTELO, A. et al. Bile acids: chemistry, physiology, and pathophysiology. World J. Gastroenterol. 15 (7), 804–816 (2009).
doi: 10.3748/wjg.15.804
pubmed: 19230041
PHELPS, T. & SNYDER, E. The influence of biological sex and sex hormones on bile acid synthesis and cholesterol homeostasis. Biol. Sex. Differ. 10 (1), 52 (2019).
doi: 10.1186/s13293-019-0265-3
pubmed: 31775872
CHIANG J Y. Bile acid metabolism and signaling. Compr. Physiol. 3 (3), 1191–1212 (2013).
doi: 10.1002/cphy.c120023
pubmed: 23897684
SHAPIRO, H. et al. Bile acids in glucose metabolism in health and disease. J. Exp. Med. 215 (2), 383–396 (2018).
doi: 10.1084/jem.20171965
pubmed: 29339445
DELIĆ, D. et al. Testosterone-induced permanent changes of hepatic gene expression in female mice sustained during Plasmodium chabaudi malaria infection. J. Mol. Endocrinol. 45 (6), 379–390 (2010).
doi: 10.1677/JME-10-0026
pubmed: 20844152
JIA, W. et al. Targeting the alternative bile acid synthetic pathway for metabolic diseases. Protein Cell. 12 (5), 411–425 (2021).
doi: 10.1007/s13238-020-00804-9
pubmed: 33252713
MA, H. et al. Attenuated effects of bile acids on glucose metabolism and insulin sensitivity in a male mouse model of prenatal undernutrition. Endocrinology 158 (8), 2441–2452 (2017).
doi: 10.1210/en.2017-00288
pubmed: 28637315
YU, H. et al. Chenodeoxycholic Acid as a potential prognostic marker for Roux-en-Y gastric bypass in Chinese obese patients. J. Clin. Endocrinol. Metab. 100 (11), 4222–4230 (2015).
doi: 10.1210/jc.2015-2884
pubmed: 26425885
CARMINA E, LONGO R A. Increased prevalence of Elevated DHEAS in PCOS Women with non-classic (B or C) phenotypes: a retrospective analysis in patients aged 20 to 29 years. Cells 11(20). (2022).
ELHASSAN, Y. S. et al. Causes, patterns, and severity of androgen excess in 1205 consecutively recruited women. J. Clin. Endocrinol. Metab. 103 (3), 1214–1223 (2018).
doi: 10.1210/jc.2017-02426
pubmed: 29342266
FROMMHERZ, L. et al. Age-related changes of plasma bile acid concentrations in healthy adults–results from the cross-sectional KarMeN study. PLoS One 11 (4), e0153959 (2016).
doi: 10.1371/journal.pone.0153959
pubmed: 27092559